31 , 32 Although only the proteomic measure of body fat percentage was significantly different between empagliflozin‐treated versus placebo, clear trends in cardiovascular risk reduction and improved kidney prognosis were observed and approached significance (using unadjusted P values).
← all excerpts
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
1
—
—